CN104274702A - Traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness - Google Patents
Traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness Download PDFInfo
- Publication number
- CN104274702A CN104274702A CN201410551071.0A CN201410551071A CN104274702A CN 104274702 A CN104274702 A CN 104274702A CN 201410551071 A CN201410551071 A CN 201410551071A CN 104274702 A CN104274702 A CN 104274702A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- herba
- medicine preparation
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 14
- 239000008280 blood Substances 0.000 title claims abstract description 13
- 210000004369 blood Anatomy 0.000 title claims abstract description 13
- 230000007812 deficiency Effects 0.000 title claims abstract description 9
- 206010019280 Heart failures Diseases 0.000 title abstract description 8
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 241000481592 Actinostemma Species 0.000 claims abstract description 10
- 241000921438 Plagiopus oederianus Species 0.000 claims abstract description 10
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 13
- 240000008397 Ganoderma lucidum Species 0.000 claims description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 9
- 241001617284 Pedicularis rex Species 0.000 claims description 9
- 241000195879 Polytrichum Species 0.000 claims description 9
- 241000001350 Pterygiella tenuisecta Species 0.000 claims description 9
- 230000000694 effects Effects 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 230000035619 diuresis Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract 2
- 241000722826 Ardisia Species 0.000 abstract 1
- 241000220457 Crotalaria Species 0.000 abstract 1
- 241000733421 Epipactis Species 0.000 abstract 1
- 241000983593 Ficus lyrata Species 0.000 abstract 1
- 241000222336 Ganoderma Species 0.000 abstract 1
- 235000003956 Luffa Nutrition 0.000 abstract 1
- 244000050983 Luffa operculata Species 0.000 abstract 1
- 241000167859 Pedicularis Species 0.000 abstract 1
- 241000001348 Phtheirospermum Species 0.000 abstract 1
- 244000207867 Pistia stratiotes Species 0.000 abstract 1
- 235000006440 Pistia stratiotes Nutrition 0.000 abstract 1
- 235000000656 Rosa multiflora Nutrition 0.000 abstract 1
- 244000050053 Rosa multiflora Species 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000003813 thumb Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 10
- 230000004217 heart function Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 5
- 230000010354 integration Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010012118 Defect conduction intraventricular Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013974 Dyspnoea paroxysmal nocturnal Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010051448 Hepatojugular reflux Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness. The treatment of the disease according to the dialectical therapy of traditional Chinese medicine is favorable for benefiting qi for activating blood circulation as well as promoting diuresis and clearing damp. Therefore, according to the invention, Chinese herbal medicines such as king pedicularis roots, glossy ganoderma, rust-brown crotalaria, papillose epipactis, ficus lyrata, luffa roots, tiny ardisia, rosa multiflora thumb, waterlettuce herbs, lobed actinostemma herbs, finelydivided phtheirospermum and plagiopus oederi limpr are selected and then decocted with water into a decoction in a manufacturing laboratory of the institute; and clinical trials show that the curative effect of a treatment group is superior to that of a control group, and the preparation has less side effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly relate to the Chinese medicine preparation of a kind of chronic heart failure blood stasis due to qi deficiency, syndrome of internal stagnation of fluid-dampness.
Background technology
Chronic heart failure (CHF) is the final home to return to of most of cardiovascular disease, is also the topmost cause of death of cardiovascular disease.Along with the continuous intensification of aging, the sickness rate of this disease presents ascendant trend, and 5 years case fatality rate of its case fatality rate and malignant tumor are substantially similar, and the existence of the serious harm mankind is healthy.Treatment chronic heart failure is very urgent.The clinical treatment of current chronic heart failure is still based on western medical treatment, along with everybody deepening continuously to chronic heart failure understanding, the Therapeutic mode of modern medicine changes, while improving clinical symptoms, link and the long-term prognosis of risk factor are more noted, reduce mortality rate, improve the quality of life etc. of patient.Although modern medicine development, the sickness rate of heart failure, admission rate, mortality rate still cannot well control.Clinical practice for many years proves, utilizes Chinese medicine chronic heart failure to have good curative effect, and is easily accepted by patient, safe and reliable, has no its toxic and side effects.
Summary of the invention
The object of this invention is to provide the Chinese medicine preparation of a kind of chronic heart failure blood stasis due to qi deficiency, syndrome of internal stagnation of fluid-dampness.The suitable benefiting QI for activating blood circulation of this disease of dialectical treatment, diuretic damp eliminating.
The object of the invention is to be achieved through the following technical solutions, the Chinese medicine preparation of this chronic heart failure blood stasis due to qi deficiency, syndrome of internal stagnation of fluid-dampness is made up of the Chinese medicine of following weight portion: Pedicularis rex C. B. Clarke ex Maxim. 25-30 part, Ganoderma lucidum seu Japonicum 1-2 part, Herba Crotalariae Ferrugineae 10-20 part, Herba Epipactidis papillosae 10-15 part, Caulis et Folium Fici beecheyanae 20-40 part, Radix Luffae 3-6 part, Herba Ardisiae Pusillae 3-8 part, Fructus rosae multiflorae 5-10 part, Herba Pistiae 15-25 part, Lobed Actinostemma Herb 10-20 part, Phtheirospermum tenuisectum Bur.et Franch. 6-12 part, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 10-15 part.
Preferably, Pedicularis rex C. B. Clarke ex Maxim. 27 parts, Ganoderma lucidum seu Japonicum 1.5 parts, Herba Crotalariae Ferrugineae 15 parts, Herba Epipactidis papillosae 12 parts, Caulis et Folium Fici beecheyanae 30 parts, Radix Luffae 5 parts, Herba Ardisiae Pusillae 5 parts, Fructus rosae multiflorae 7 parts, Herba Pistiae 20 parts, Lobed Actinostemma Herb 15 parts, Phtheirospermum tenuisectum Bur.et Franch. 9 parts, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 13 parts.
Above-mentioned Chinese medicine decocting is made decoction by preparation method.
Fang Zhong: Pedicularis rex C. B. Clarke ex Maxim. benefiting vital QI and blood, invigorating spleen to remove dampness; Ganoderma lucidum seu Japonicum benefiting vital QI and blood, relieving cough and asthma, analgesia; Herba Crotalariae Ferrugineae invigorating the spleen and replenishing QI, invigorating spleen for diuresis; Herba Epipactidis papillosae invigorating the spleen and replenishing QI, Shu Yu and in; Caulis et Folium Fici beecheyanae invigorating the spleen and replenishing QI, bone and muscle strengthening; Radix Luffae is invigorated blood circulation, stimulate the menstrual flow, subside a swelling; Herba Ardisiae Pusillae promoting blood circulation to remove obstruction in the collateral; The relieving restlessness of Fructus rosae multiflorae diuretic, removing toxic substances are invigorated blood circulation; The dehumidifying of Herba Pistiae diuretic, removing heat from blood, to invigorate blood circulation; Lobed Actinostemma Herb inducing diuresis to remove edema; Phtheirospermum tenuisectum Bur.et Franch. nourishes heart, calm the nerves, stop blooding; Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) tranquilizing mind.
Clinical data
1, this research of physical data case is all from May, 2010 my Out-patient Department and inpatient of in December ,-2011, and MethodsThe cases enrolled 60 example, is divided into matched group and treatment group at random altogether, often organizes each 30 examples.Patient age scope 41-87 year, the mean age is 60.7 years old, wherein male 32 example, women 28 example.Two groups at the age, sex, cardiac functional grading, the equal not statistically significants of aspect difference such as heart failure integration.
2, diagnostic criteria is with reference to the kit for diagnosing heart failure standard of " guideline of clinical investigations of new Chinese medicine treatment heart failure ".Main standard: paroxysmal nocturnal dyspnea or orthopnea; Pulmonary's sound of vomiting sound; Neck neck arteries and veins anger is opened; Acute lung edema; Third heart sound gallop; Cardiac dilatation; Hepatojugular reflux sun.Minor criteria: ankle edema or (with) hypourocrinia; Nocturnal cough's (eliminating upper respiratory tract infection); Dyspnea after movable; Hepatomegaly; Hydrothorax; Tachycardia (heart rate >=120 beat/min); In treatment heart failure five days, patient body weight alleviates 4.5kg.
Chronic heart failure blood stasis due to qi deficiency, syndrome of internal stagnation of fluid-dampness differential diagnosis in tcm disease: 1. primary symptom: cardiopalmus, breathe hard, uncomfortable in chest, edema of lower limbs.2. secondary disease: weak, dim complexion, cervical region blue veins exposes, and cyanosis of the lips and nails, coughs up and tell frothy sputum, oliguria, abdominal distention.3. tongue arteries and veins: dimly pale tongue or have ecchymosis, Tai Bai or whiten, thready pulse is short, hesitant pulse or irregularly intermittent and regularly intermittent pulse.Above primary symptom is indispensable, and secondary disease has more than 2 concurrently, in conjunction with tongue arteries and veins and diagnosable.
3, Therapeutic Method matched group patient carries out western medicine routine treatment: 1. ACEI-Lisinopril Tablets in Chinese Volunteers must be applied, maybe can not tolerate unless there are contraindication, every daily dose from minimum dosage (2.5mg/d) if tolerance, every 3-7 days, dosage doubles, target dose is 5-20mg/d, and process need notes individuation; 2. diuretic-hydrochlorothiazide tablet, every have fluid retention evidence or once had fluid retention medical history, all needs oral hydrochlorothiazide tablet, from minimum dose 25mg/d, 100mg/d reaches ceiling effect, maintains take with maintenance dose for a long time after Morbidity control with minimum dose; 3. digoxin-suggestion first uses ACEI, and add with digoxin if Symptoms last exists, digoxin is with maintenance dose therapy:
0.125-0.25mg/d。Treatment group uses Chinese medicine preparation of the present invention on the basis of western medical treatment, take Pedicularis rex C. B. Clarke ex Maxim. 27g, Ganoderma lucidum seu Japonicum 1.5g, Herba Crotalariae Ferrugineae 15g, Herba Epipactidis papillosae 12g, Caulis et Folium Fici beecheyanae 30g, Radix Luffae 5g, Herba Ardisiae Pusillae 5g, Fructus rosae multiflorae 7g, Herba Pistiae 20g, Lobed Actinostemma Herb 15g, Phtheirospermum tenuisectum Bur.et Franch. 9g, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 13g, decocting makes decoction, every day potion, the half an hour of each sub-service sooner or later after meal, within 4 weeks, be a course for the treatment of, treat 4 weeks all continuously for two groups.
Nursing should be noted assist patient to get the clinostatism being conducive to breathing, as high pillow clinostatism, semirecumbent position, sit up straight clinostatism.For patient provides quiet, comfortable environment, keep ward air fresh, timing ventilation is taken a breath.Give (suitably) oxygen according to patient's degree of oxygen deficiency to suck.Assist patient to stand up, clap the back of the body, be beneficial to sputum and discharge, keep respiratory passage unblocked.
4, criterion of therapeutical effect is with reference to " new Chinese medicine guideline of clinical investigations " (trial version in 2002).
(1) cardiac function curative effect determinate standard
Effective: heart failure basic controlling or cardiac function improve more than 2 grades persons.
Effective: cardiac function improves 1 grade, but not as good as 2 grades of persons.
Invalid: cardiac function improves less than 1 grade of person.
Worsen: cardiac function worsens more than 1 grade or 1 grade.
(2) ECG curative effect criterion
Effective: electrocardiogram returns to " roughly normal " or reach " normal ECG ".
Effective: the reduction of ST section, to treat rear more than rise 0.05mV, but do not reach normal level, shoal (reaching more than 25% person) at the negative T wave that mainly leads; Or T ripple becomes uprightly from smooth, chamber or intraventricular block improver.
Invalid: electrocardiogram is substantially identical with before treatment.
Increase the weight of: ST section reduces more than 0.05mV before comparatively treating, deepen (reaching more than 25%) or upright T ripple flattens smooth at the negative T wave that mainly leads, smooth T ripple becomes to be inverted, and occurs ectopic cardiac rhythm, atrioventricular block or intraventricular block person.
(3) tcm syndrome curative effect determinate standard
Effective: cardinal symptom, minor symptom disappear substantially, after treatment, syndrome integral reduces >=70%.
Effective: after treatment, syndrome integral reduces >=30%.
Invalid: after treatment, syndrome integral reduces < 30%.
Increase the weight of: after treatment, syndrome integral reduces < 0.
Note: computing formula: [before (before treatment the rear integration of integration-treatment)/treatment integration] × 100%
5, therapeutic outcome
Table 1 liang group Cardiac Function of Patients comparitive study
| Group | Number of cases | Effective | Effectively | Invalid | Worsen | Total effective rate |
| Treatment group | 30 | 6 | 19 | 5 | 0 | 83.33％ |
| Matched group | 30 | 3 | 15 | 10 | 2 | 60.00％ |
Two groups of cardiac function comparitive study after treatment, P=0.008 < 0.05.There were significant differences.Treatment group is improved cardiac function curative effect and is better than matched group.
Table 2 liang group patient ECG comparitive study
| Group | Number of cases | Effective | Effectively | Invalid | Increase the weight of | Total effective rate |
| Treatment group | 30 | 4 | 15 | 11 | 0 | 63.33％ |
| Matched group | 30 | 3 | 15 | 12 | 0 | 60.00％ |
Two groups of patient ECG's comparitive study after treatment, P > 0.05.Without significant difference.It is suitable that treatment group and matched group improve ECG curative effect.
A table 3 liang group patient traditional Chinese medical science total effects compares
| Group | Number of cases | Effective | Effectively | Invalid | Increase the weight of | Total effective rate |
| Treatment group | 30 | 7 | 19 | 4 | 0 | 86.67％ |
| Matched group | 30 | 3 | 16 | 11 | 0 | 63.33％ |
After treatment, two groups of traditional Chinese medical science total effectses compare, P=0.020 < 0.05.There were significant differences.Treatment group is improved tcm symptom curative effect and is better than matched group.
During clinical application, treatment group patient has no the symptom such as nausea,vomiting,diarrhea, dizziness, before and after medication, liver function, renal function and the safety indexes such as blood, routine urinalysis are without significant change, and illustrate that Chinese medicine preparation of the present invention is without obvious toxic-side effects, safety is better.Matched group patient have 3 example occur dizzy, headache symptom, 1 example occur diarrhoea symptom, adjustment dosage or drug withdrawal after transference cure.
Detailed description of the invention
Embodiment one: take Pedicularis rex C. B. Clarke ex Maxim. 27g, Ganoderma lucidum seu Japonicum 1.5g, Herba Crotalariae Ferrugineae 15g, Herba Epipactidis papillosae 12g, Caulis et Folium Fici beecheyanae 30g, Radix Luffae 5g, Herba Ardisiae Pusillae 5g, Fructus rosae multiflorae 7g, Herba Pistiae 20g, Lobed Actinostemma Herb 15g, Phtheirospermum tenuisectum Bur.et Franch. 9g, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 13g, makes decoction by above-mentioned Chinese medicine decocting.
Embodiment two: take Pedicularis rex C. B. Clarke ex Maxim. 25g, Ganoderma lucidum seu Japonicum 1g, Herba Crotalariae Ferrugineae 20g, Herba Epipactidis papillosae 10g, Caulis et Folium Fici beecheyanae 40g, Radix Luffae 3g, Herba Ardisiae Pusillae 8g, Fructus rosae multiflorae 10g, Herba Pistiae 25g, Lobed Actinostemma Herb 10g, Phtheirospermum tenuisectum Bur.et Franch. 12g, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 15g, makes decoction by above-mentioned Chinese medicine decocting.
Embodiment three: take Pedicularis rex C. B. Clarke ex Maxim. 30g, Ganoderma lucidum seu Japonicum 2g, Herba Crotalariae Ferrugineae 10g, Herba Epipactidis papillosae 15g, Caulis et Folium Fici beecheyanae 20g, Radix Luffae 6g, Herba Ardisiae Pusillae 3g, Fructus rosae multiflorae 5g, Herba Pistiae 10g, Lobed Actinostemma Herb 20g, Phtheirospermum tenuisectum Bur.et Franch. 6g, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 10g, makes decoction by above-mentioned Chinese medicine decocting.
Claims (2)
1. a Chinese medicine preparation for chronic heart failure blood stasis due to qi deficiency, syndrome of internal stagnation of fluid-dampness, is characterized in that this Chinese medicine preparation is made up of the Chinese medicine of following weight portion: Pedicularis rex C. B. Clarke ex Maxim. 25-30 part, Ganoderma lucidum seu Japonicum 1-2 part, Herba Crotalariae Ferrugineae 10-20 part, Herba Epipactidis papillosae 10-15 part, Caulis et Folium Fici beecheyanae 20-40 part, Radix Luffae 3-6 part, Herba Ardisiae Pusillae 3-8 part, Fructus rosae multiflorae 5-10 part, Herba Pistiae 15-25 part, Lobed Actinostemma Herb 10-20 part, Phtheirospermum tenuisectum Bur.et Franch. 6-12 part, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 10-15 part.
2. the Chinese medicine preparation of a kind of chronic heart failure blood stasis due to qi deficiency as claimed in claim 1, syndrome of internal stagnation of fluid-dampness, is characterized in that this Chinese medicine preparation is made up of the Chinese medicine of following weight portion: Pedicularis rex C. B. Clarke ex Maxim. 27 parts, Ganoderma lucidum seu Japonicum 1.5 parts, Herba Crotalariae Ferrugineae 15 parts, Herba Epipactidis papillosae 12 parts, Caulis et Folium Fici beecheyanae 30 parts, Radix Luffae 5 parts, Herba Ardisiae Pusillae 5 parts, Fructus rosae multiflorae 7 parts, Herba Pistiae 20 parts, Lobed Actinostemma Herb 15 parts, Phtheirospermum tenuisectum Bur.et Franch. 9 parts, Plagiopus oederi (Brid.) Limpr.(Polytrichum annotinum L.) 13 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410551071.0A CN104274702A (en) | 2014-10-08 | 2014-10-08 | Traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410551071.0A CN104274702A (en) | 2014-10-08 | 2014-10-08 | Traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104274702A true CN104274702A (en) | 2015-01-14 |
Family
ID=52250363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410551071.0A Pending CN104274702A (en) | 2014-10-08 | 2014-10-08 | Traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104274702A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800636A (en) * | 2015-04-20 | 2015-07-29 | 彭玉峰 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome with emotional disorder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101301458A (en) * | 2008-06-19 | 2008-11-12 | 常国良 | Medicament for treating chronic cardiac failure and preparation thereof |
| CN102813790A (en) * | 2012-07-28 | 2012-12-12 | 张茂根 | Traditional Chinese medicine for treating yin-yang deficiency type chronic heart failure |
-
2014
- 2014-10-08 CN CN201410551071.0A patent/CN104274702A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101301458A (en) * | 2008-06-19 | 2008-11-12 | 常国良 | Medicament for treating chronic cardiac failure and preparation thereof |
| CN102813790A (en) * | 2012-07-28 | 2012-12-12 | 张茂根 | Traditional Chinese medicine for treating yin-yang deficiency type chronic heart failure |
Non-Patent Citations (1)
| Title |
|---|
| 张艳等: "慢性心衰中医分期分级临床辨证体会", 《辽宁中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800636A (en) * | 2015-04-20 | 2015-07-29 | 彭玉峰 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome with emotional disorder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111773308A (en) | Traditional Chinese medicine composition of 'lung-ventilating and toxin-expelling decoction' for preventing and treating new coronary pneumonia and preparation method | |
| CN102302723A (en) | Traditional Chinese medicine preparation for eliminating phlegm and relieving cough | |
| CN102475868A (en) | Anti-rheumatism medicinal liquor | |
| CN104042713B (en) | A kind of Chinese medicine composition for the treatment of bronchial asthma | |
| CN103110905B (en) | Traditional Chinese medical preparation for treating cholecystitis with stagnation of liver qi and spleen deficiency | |
| CN104069358A (en) | Chinese herba preparation for treating bronchial asthma | |
| CN101406611B (en) | Chinese medicine preparation for treating bronchial asthma | |
| CN104274702A (en) | Traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness | |
| CN103638488A (en) | Traditional Chinese medicine composition for treating pleurisy | |
| CN103393909B (en) | Chinese medicinal preparation for treating biliary calculus with cholecystitis | |
| CN103212041B (en) | Chinese medicinal composition treating coronary heart disease | |
| CN104644952A (en) | Traditional Chinese medicine preparation for treating cold-dampness type chronic lumbar strain | |
| CN102743708B (en) | Cordyceps sinensis and gecko powder for treating emphysema pulmonary heart disease asthma chronic bronchitis | |
| CN106581612A (en) | Traditional Chinese medicine recipe for treating pulmonary heart disease | |
| CN103263645B (en) | Gastritis and gastric ulcer treatment drug | |
| CN107617091A (en) | A kind of Chinese medicine composition for treating cold asthma | |
| CN101385812B (en) | Traditional Chinese medicine composition containing epimeddium for treating dermatomyositis and preparation thereof | |
| CN101979056A (en) | Traditional Chinese medicament for treating asthma | |
| CN100444877C (en) | A Chinese medicine for treating cholecystitis | |
| CN106177561A (en) | One treats phthisical Chinese medicine composition | |
| CN106074784A (en) | The Chinese medicine for the treatment of coronary heart disease and myocardial ischemia | |
| CN105582280A (en) | Traditional Chinese medicine preparation for treating angina pectoris of coronary heart disease | |
| Xu | TCM and Western Medicine: Diagnosis and Treatment of Novel Coronavirus Pneumonia, A Case Study | |
| CN104225435A (en) | Traditional Chinese medicine preparation for treating turbid phlegm obstructing type coronary heart disease | |
| CN103356970A (en) | Traditional Chinese medicine composition for treating mammary gland hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Jiang Zhiming Inventor after: Sun Nannan Inventor after: Li Chong Inventor after: Zhang Zhonghui Inventor before: Jiang Zhiming |
|
| COR | Change of bibliographic data | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150114 |